Business Wire

65 Percent of Global Businesses Ill-Equipped to Defend Against Email-Based Cyber-Attacks

Del

Mimecast (NASDAQ: MIME), the email security, email continuity and email archiving cloud company, today released the results of its new global research study: Mimecast Business Email Threat Report 2016, Email Security Uncovered. The survey of 600 IT security professionals, shows that while 64 percent regard email as a major cyber-security threat to their business, 65 percent don’t feel fully equipped or up to date to reasonably defend against email-based attacks. One-third of respondents also believe their email is more vulnerable today than it was five years ago.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160217005374/en/

65 Percent of Global Businesses Ill-Equipped to Defend Against Email-Based Cyber-Attacks (Photo: Bus ...

65 Percent of Global Businesses Ill-Equipped to Defend Against Email-Based Cyber-Attacks (Photo: Business Wire)

Email continues to be a critical technology in business and the threat of email hacks and data breaches loom large over IT security managers. Consequently, confidence and experience with previous data breaches and email hacks play key parts in determining a company’s perceived level of preparedness against these threats and targeted email attacks.

Of the 600 surveyed, just 35 percent feel confident about their level of preparedness against data breaches. Of the 65 percent who don’t feel fully prepared against future potential attacks, nearly half experienced such attacks in the past, indicating that they don’t feel any more protected following an attack than they did prior.

This is also reflected in the few steps taken toward widespread email security. Although 83 percent of all respondents highlight email as a common attack vector, one out of ten report not having any kind of email security training in place. Among the least-confident respondents, 23 percent attest to lacking any supplementary security measures.

“Our cyber-security is under attack and we depend on technology, and email in particular, in all aspects of business. So it’s very disconcerting to see that while we might appreciate the danger, many companies are still taking too few measures to defend themselves against email-based threats in particular,” said Peter Bauer, chief executive officer, Mimecast. “As the cyber threat becomes more grave, email attacks will only become more common and more damaging. It’s essential that executives, the C-suite in particular, realize that they may not be as safe as they think and take action. Our research shows there is work still to be done to be safe and we can learn a lot from the experience of those that have learnt the hard way.”

Budget and C-suite involvement were the biggest gaps found between the most and least prepared respondents. Among the IT security managers who feel most prepared, five out of six say that their C-suite is engaged with email security. However, of all IT security managers who were polled, only 15 percent say their C-suite is extremely engaged in email security, while 44 percent say their C-suite is only somewhat engaged, not very engaged, or not engaged at all.

Those who feel better prepared to handle email-based threats also allocate higher percentages of their IT security budgets toward email security. These IT security managers allocate 50 percent higher budgets to email security compared to managers who were less confident in their readiness. From these findings, the data points to allotting 10.4 percent of the total IT budget toward email security as the ideal intersection between email security confidence and spend.

Mimecast found that five distinct “personas” emerged among the respondents, and characterized them into a Cyber-Security Shiver Grid based on their levels of email security and perceptions of data breach confidence: the Vigilant (16 percent), Equipped Veterans (19 percent), Apprehensive (31 percent), Nervous (6 percent) and Battle-Scarred (28 percent). Altogether, a majority of the IT security managers – totaling 65 percent, comprising the apprehensive, nervous and battle-scarred respondents – feel unprepared to manage email-based attacks.

Other key findings of the survey include:

  • The top 20 percent of organizations that feel most secure are 250 percent more likely to see email as their biggest vulnerability.
  • Confident IT security managers are 2.7x more likely to have a C-suite that is extremely or very engaged in email security. They are also 1.6x more likely to see C-suite involvement in email security as extremely or very appropriate.
  • The least confident IT security managers are more likely to be using Microsoft’s Exchange Mail Server 2010, which ended mainstream support in January 2015. The most confident managers are more likely to use the up-to-date Exchange Server 2013.
  • 70 percent of IT professionals that have recently and directly experienced an email hack employ internal safeguards, such as data leak prevention or targeted threat protection.
  • Apprehensive IT security professionals are more likely to be found in smaller (fewer than 500 employees) firms than larger ones (32 percent to 18 percent, respectively).
  • Less than half (48 percent) of IT security managers in smaller firms feel confident and well-prepared for tackling email security threats, compared to larger companies.

This study was created by Mimecast and March Communications, and facilitated by Vanson Bourne, during late 2015, consisting of 600 IT security decision makers from the USA (n=200), the UK (n=200), South Africa (n=100) and Australia (n=100) on their companies’ level of email security, IT preparedness and confidence in defending against cyber threats, as well as past experiences with data breaches and email hacks. The overall margin of error is ± 4 percent at the 95 percent confidence level. For more information, or to download the full research report, click here.

About Mimecast
Mimecast makes business email and data safer for 16,200 customers and millions of employees worldwide. Founded in 2003, the Company's next-generation cloud-based security, archiving and continuity services protect email and deliver comprehensive email risk management in a single, fully-integrated subscription service. Mimecast reduces email risk and the complexity and cost of managing the array of point solutions traditionally used to protect email and its data. For customers that have migrated to cloud services like Microsoft Office 365, Mimecast mitigates single vendor exposure by strengthening security coverage, combating downtime and improving email archiving.

Mimecast Email Security protects against malware, spam, advanced phishing and other emerging attacks, while preventing data leaks. Mimecast Mailbox Continuity enables employees to continue using email during planned and unplanned outages. Mimecast Enterprise Information Archiving unifies email, file and instant messaging data to support e-discovery and give employees fast access to their personal archive via PC, Mac and mobile apps.

Visit our home page at: www.mimecast.com.

Contact information

U.S. Press Contact
March Communications
Stephanie Jackman, +1 617-960-9875
mimecast@marchcomms.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00Pressemelding

ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number

GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01Pressemelding

GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom